Mode
Text Size
Log in / Sign up
Phase 4 N=32 Randomized Single-blind Treatment

Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity

Stroke · Brain Injuries · Spasticity

Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Jan 2021
Primary outcome: Primary: Spastic Hypertonia as Measured by the Ashworth Scale — 2.4; 2.33; 2.36 score on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Botox (Drug)
Age
Pediatric, Adult, Older Adult · 12+ yrs
Sex
All
Sponsor
The University of Texas Health Science Center, Houston
Primary completion
Mar 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Spastic Hypertonia as Measured by the Ashworth Scale
1.42; 1.13; 1.1
PRIMARY
Spastic Hypertonia as Measured by the Ashworth Scale
1.42; 1.13; 1.1
PRIMARY
Spastic Hypertonia as Measured by the Ashworth Scale
1.42; 1.13; 1.1
PRIMARY
Spastic Hypertonia as Measured by the Ashworth Scale
1.42; 1.13; 1.1
PRIMARY
Spastic Hypertonia as Measured by the Ashworth Scale
1.42; 1.13; 1.1
SECONDARY
Range of Motion as Measured by Goniometry
-1.82; 2.25; -2.30
SECONDARY
Range of Motion as Measured by Goniometry
-1.82; 2.25; -2.30

Summary

The study seeks to compare the effectiveness of three preparations of BOTOX-A® in treating muscle tightness and spasms in the feet and ankles of people with stroke.

Eligibility Criteria

Inclusion Criteria -

  • Spasticity resulting from ABI (stroke, including vascular malformations, traumatic brain injury)
  • Ashworth Score (resting) of at least 2 of the primary ankle plantarflexor (gastrocnemius)
  • Onset of primary illness at least six months prior to study inclusion
  • At least 12 years of age

Exclusion Criteria -

  • Hypersensitivity or allergy to botulinum toxin
  • History of myasthenia gravis or other neuromuscular disease
  • Current use of aminoglycosides
  • Botulinum toxin or phenol injection to study limb within six months prior to recruitment
  • Current use of other spasmolytic drug, such as diazepam, baclofen, dantrolene, tizanidine
  • Presence of contracture or significant muscle atrophy
  • Pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00178646). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search